Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Mol Carcinog. 2020 May 11;59(8):955–966. doi: 10.1002/mc.23214

Figure 4:

Figure 4:

Effect of HDAC inhibitors on class I HDAC expression and histone H3/H4 acetylation in prostate cancer cells. (A) Human prostate cancer LNCaP and (B) DU145 cells treated with indicated concentrations of NaB and TSA for 48 h. The lysates were prepared, electrophoresed by SDS‐PAGE, followed by immunoblotting with HDAC 1, 2, 3 and 8 antibodies. β-actin serves as loading control. Histone extraction was performed on cells treated with HDAC inhibitors for 48 h. The immunoblots were probed for acetylated anti-Histone H3/H4 antibodies. Total histone H3/H4 serves as loading control.